

Third-Generation-Sequencing: Chancen für die Transfusionsmedizin

Literaturhinweise / Quellenangaben

1. F. Sanger, S. Nicklen, und A. R. Coulson, „DNA sequencing with chain-terminating inhibitors“, Proc. Natl. Acad. Sci., Bd. 74, Nr. 12, S. 5463–5467, Dez. 1977, doi: 10.1073/pnas.74.12.5463.
2. International Human Genome Sequencing Consortium u. a., „Initial sequencing and analysis of the human genome“, Nature, Bd. 409, Nr. 6822, S. 860–921, Feb. 2001, doi: 10.1038/35057062.
3. S. Nurk u. a., „The complete sequence of a human genome“, Science, Bd. 376, Nr. 6588, S. 44–53, Apr. 2022, doi: 10.1126/science.abj6987.
4. A. Yang, W. Zhang, J. Wang, K. Yang, Y. Han, und L. Zhang, „Review on the Application of Machine Learning Algorithms in the Sequence Data Mining of DNA“, Front. Bioeng. Biotechnol., Bd. 8, S. 1032, Sep. 2020, doi: 10.3389/fbioe.2020.01032.
5. H. Satam u. a., „Next-Generation Sequencing Technology: Current Trends and Advancements“, Biology, Bd. 12, Nr. 7, S. 997, Juli 2023, doi: 10.3390/biology12070997.
6. T. Hu, N. Chitnis, D. Monos, und A. Dinh, „Next-generation sequencing technologies: An overview“, Hum. Immunol., Bd. 82, Nr. 11, S. 801–811, Nov. 2021, doi: 10.1016/j.humimm.2021.02.012.
7. D. Fürst, C. Tsamadou, C. Neuchel, H. Schrezenmeier, J. Mytilineos, und C. Weinstock, „Next-Generation Sequencing Technologies in Blood Group Typing“, Transfus. Med. Hemotherapy Off. Organ Dtsch. Ges. Transfusionsmedizin Immunhamatologie, Bd. 47, Nr. 1, S. 4–13, Feb. 2020, doi: 10.1159/000504765.
8. C. F. Minervini u. a., „Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities“, Front. Genet., Bd. 11, Feb. 2020, doi: 10.3389/fgene.2020.00076.
9. C. Scarano, I. Veneruso, R. R. De Simone, G. Di Bonito, A. Secondino, und V. D’Argenio, „The Third-Generation Sequencing Challenge: Novel Insights for the Omic Sciences“, Biomolecules, Bd. 14, Nr. 5, S. 568, Mai 2024, doi: 10.3390/biom14050568.
10. A. Rhoads und K. F. Au, „PacBio Sequencing and its Applications“, Genomics Proteomics Bioinformatics, Bd. 13, Nr. 5, S. 278–289, Okt. 2015, doi: 10.1016/j.gpb.2015.08.002.
11. I. M. Derrington u. a., „Nanopore DNA sequencing with MspA“, Proc. Natl. Acad. Sci. U. S. A., Bd. 107, Nr. 37, S. 16060–16065, Sep. 2010, doi: 10.1073/pnas.1001831107.
12. S. L. Amarasinghe, S. Su, X. Dong, L. Zappia, M. E. Ritchie, und Q. Gouil, „Opportunities and challenges in long-read sequencing data analysis“, Genome Biol., Bd. 21, Nr. 1, S. 30, Dez. 2020, doi: 10.1186/s13059-020-1935-5.
13. Q. Deng u. a., „Nanopore-based metagenomic sequencing for the rapid and precise detection of pathogens among immunocompromised cancer patients with suspected infections“, Front. Cell. Infect. Microbiol., Bd. 12, S. 943859, Sep. 2022, doi: 10.3389/fcimb.2022.943859.
14. X. Chen, H. Xu, X. Shu, und C.-X. Song, „Mapping epigenetic modifications by sequencing technologies“, Cell Death Differ., Bd. 32, Nr. 1, S. 56–65, Jan. 2025, doi: 10.1038/s41418-023-01213-1.
15. B. D. Sigurpalsdottir u. a., „A comparison of methods for detecting DNA methylation from long-read sequencing of human genomes“, Genome Biol., Bd. 25, Nr. 1, S. 69, März 2024, doi: 10.1186/s13059-024-03207-9.

16. J. Quick u. a., „Real-time, portable genome sequencing for Ebola surveillance“, *Nature*, Bd. 530, Nr. 7589, S. 228–232, Feb. 2016, doi: 10.1038/nature16996.
17. A. Payne, N. Holmes, T. Clarke, R. Munro, B. J. Debebe, und M. Loose, „Readfish enables targeted nanopore sequencing of gigabase-sized genomes“, *Nat. Biotechnol.*, Bd. 39, Nr. 4, S. 442–450, Apr. 2021, doi: 10.1038/s41587-020-00746-x.
18. E. Hershberg, „Illumina: The Measurement Monopoly“, 17. September 2023. Zugegriffen: 25. Juli 2025. [Online]. Verfügbar unter: <https://centuryofbio.com/p/illumina>
19. I. Mobley, „How did Illumina dominate the sequencing market?“ Zugegriffen: 25. Juli 2025. [Online]. Verfügbar unter: <https://frontlinegenomics.com/how-did-illumina-monopolize-the-sequencing-market>
20. A. Chera, M. Stancu-Cretu, N. R. Zabet, und O. Bucur, „Shedding light on DNA methylation and its clinical implications: the impact of long-read-based nanopore technology“, *Epigenetics Chromatin*, Bd. 17, Nr. 1, Dez. 2024, doi: 10.1186/s13072-024-00558-2.
21. M. U. Ahsan, Q. Liu, J. E. Perdomo, L. Fang, und K. Wang, „A survey of algorithms for the detection of genomic structural variants from long-read sequencing data“, *Nat. Methods*, Bd. 20, Nr. 8, S. 1143–1158, Aug. 2023, doi: 10.1038/s41592-023-01932-w.
22. Z. Liu, R. Roberts, T. R. Mercer, J. Xu, F. J. Sedlazeck, und W. Tong, „Towards accurate and reliable resolution of structural variants for clinical diagnosis“, *Genome Biol.*, Bd. 23, Nr. 1, S. 68, März 2022, doi: 10.1186/s13059-022-02636-8.
23. Y. Pei u. a., „A Comparison of Structural Variant Calling from Short-Read and Nanopore-Based Whole-Genome Sequencing Using Optical Genome Mapping as a Benchmark“, *Genes*, Bd. 15, Nr. 7, S. 925, Juli 2024, doi: 10.3390/genes15070925.
24. S. Martin, D. Heavens, Y. Lan, S. Horsfield, M. D. Clark, und R. M. Leggett, „Nanopore adaptive sampling: a tool for enrichment of low abundance species in metagenomic samples“, *Genome Biol.*, Bd. 23, Nr. 1, S. 11, Dez. 2022, doi: 10.1186/s13059-021-02582-x.
25. M. Gueuning u. a., „Haplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants“, *Blood Adv.*, Bd. 7, Nr. 6, S. 878–892, März 2023, doi: 10.1182/bloodadvances.2022007133.
26. S. G. Sandler u. a., „It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group“, *Transfusion (Paris)*, Bd. 55, Nr. 3, S. 680–689, März 2015, doi: 10.1111/trf.12941.
27. M. Gueuning u. a., „Resolving Genotype-Phenotype Discrepancies of the Kidd Blood Group System Using Long-Read Nanopore Sequencing“, *Biomedicines*, Bd. 12, Nr. 1, S. 225, Jan. 2024, doi: 10.3390/biomedicines12010225.
28. C. M. Westhoff, „Blood group genotyping“, *Blood*, Bd. 133, Nr. 17, S. 1814–1820, Apr. 2019, doi: 10.1182/blood-2018-11-833954.
29. M. Li u. a., „Integrated analyses reveal unexpected complex inversion and recombination in RH genes“, *Blood Adv.*, Bd. 8, Nr. 12, S. 3154–3165, Juni 2024, doi: 10.1182/bloodadvances.2023012147.
30. M. Schmidt u. a., „First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany“, *Transfusion (Paris)*, Bd. 49, Nr. 9, S. 1836–1844, Sep. 2009, doi: 10.1111/j.1537-2995.2009.02203.x.
31. F. Tagini und G. Greub, „Bacterial genome sequencing in clinical microbiology: a pathogen-oriented review“, *Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol.*, Bd. 36, Nr. 11, S. 2007–2020, Nov. 2017, doi: 10.1007/s10096-017-3024-6.

32. K. N. Govender, T. L. Street, N. D. Sanderson, und D. W. Eyre, „Metagenomic Sequencing as a Pathogen-Agnostic Clinical Diagnostic Tool for Infectious Diseases: a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies“, *J. Clin. Microbiol.*, Bd. 59, Nr. 9, S. e02916–20, Aug. 2021, doi: 10.1128/JCM.02916–20.
33. Y. Guo u. a., „A dual-process of targeted and unbiased Nanopore sequencing enables accurate and rapid diagnosis of lower respiratory infections“, *eBioMedicine*, Bd. 98, S. 104858, Dez. 2023, doi: 10.1016/j.ebiom.2023.104858.
34. S. Hoffmann u. a., „Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial“, *eBioMedicine*, Bd. 113, S. 105613, März 2025, doi: 10.1016/j.ebiom.2025.105613.
35. R. Fu u. a., „Metagenomic Next-Generation Sequencing in the Diagnosis of Pulmonary Infections after Allogeneic Hematopoietic Stem Cell Transplantation“, *Transplant. Cell. Ther.*, Bd. 30, Nr. 11, S. 1110.e1–1110.e10, Nov. 2024, doi: 10.1016/j.jtct.2024.08.014.
36. H. Zhang u. a., „The application of targeted nanopore sequencing for the identification of pathogens and resistance genes in lower respiratory tract infections“, *Front. Microbiol.*, Bd. 13, S. 1065159, Dez. 2022, doi: 10.3389/fmicb.2022.1065159.
37. E. Sauerborn u. a., „Detection of hidden antibiotic resistance through real-time genomics“, *Nat. Commun.*, Bd. 15, Nr. 1, S. 5494, Juni 2024, doi: 10.1038/s41467-024-49851-4.
38. E. Crawford u. a., „Investigating Transfusion-related Sepsis Using Culture-Independent Metagenomic Sequencing“, *Clin. Infect. Dis.*, Bd. 71, Nr. 5, S. 1179–1185, Aug. 2020, doi: 10.1093/cid/ciz960.
39. D. Candotti, S. J. Drews, H. M. Faddy, und ISBT Transfusion-Transmitted Infectious Diseases Working Party, Subgroup on Viruses, „Monitoring viral genomic sequences in transfusion-transmitted viruses“, *Vox Sang.*, Bd. 118, Nr. 7, S. 551–558, Juli 2023, doi: 10.1111/vox.13444.
40. C. Lu, A. Bonini, J. H. Viel, und G. Maglia, „Toward single-molecule protein sequencing using nanopores“, *Nat. Biotechnol.*, Bd. 43, Nr. 3, S. 312–322, März 2025, doi: 10.1038/s41587-025-02587-y.
41. K. Motone u. a., „Multi-pass, single-molecule nanopore reading of long protein strands“, *Nature*, Bd. 633, Nr. 8030, S. 662–669, Sep. 2024, doi: 10.1038/s41586-024-07935-7.
42. J. J. Kasianowicz, E. Brandin, D. Branton, und D. W. Deamer, „Characterization of individual polynucleotide molecules using a membrane channel“, *Proc. Natl. Acad. Sci.*, Bd. 93, Nr. 24, S. 13770–13773, Nov. 1996, doi: 10.1073/pnas.93.24.13770.